BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  Drug Development

  The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty

  In the current legal and political landscape, it is all about survival for DEI initiatives.

  March 3, 2025

   · 

  1 min read
• 

  Immunology and inflammation

  AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion

  The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the first half of 2025.

  March 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Immunology and inflammation

  First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader

  Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children with one or more food allergies.

  March 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra

  AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.

  March 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pain

  Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure

  Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III trials before long.

  March 3, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Obesity

  FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment

  Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate an evolving mindset toward treating obesity as a chronic disease.

  March 3, 2025

   · 

  7 min read

   · 

  Kate Goodwin
• 

  Cancer

  The Search for the Next Keytruda: Immuno-Oncology’s Next Play

  More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.

  March 3, 2025

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Europe

  Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion

  Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.

  March 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Phase III

  Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

  Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.

  March 3, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Depression

  Neumora Shakes Up Phase III MDD Trials After January Miss

  After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.

  March 3, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky